120,902 research outputs found
Intrauterine Insemination Success Rates Between Patients TSH Level of 2.5 mIU/L and 2.5-4.5 mIU/L
No full textThe aim of this study to assess whether there is a need to decrease the TSH level below 2.5 mIU/L in unexplainable infertility patients who were undergoing intrauterine insemination and determining the difference between patients with a TSH level of 2.5 mIU / L and patients with a TSH level of 2.5-4.5 mIU/L in terms of the success of intrauterine insemination. This study conduct via cross-sectional examinations of the 272 patients who applied to Ümraniye Training and Research Hospital infertility outpatient clinic between 01.06.2017-01.10.2019, who underwent intrauterine insemination with the diagnosis of unexplained infertility. Results research the mean age of the cases participating in our study is 31.65 ± 5.28, and the mean BMI measured as 24.17 ± 4.30 kg / m2. TSH values range from 0.3 to 5.2, with an average of 1.84 ± 0.93; while TSH value of 174 cases (77.3%) is below 2.5 mIU/L, TSH value of 51 cases (22.7%) is between 2.5-4.5mIU/L. Within the control group with TSH <2.5 mIU/L, the cycle was canceled in 13 cases (7.5%), pregnancy did not occur in 143 cases (82.2%). While ongoing pregnancy was achieved in 17 cases (9.8%), clinical pregnancy was achieved in 1 case (0,6%). Also, within the study group with a TSH value of 2.5-4.5 mIU/L, cycles were canceled in 7 cases (13.7%), pregnancy did not occur in 40 cases (78.4%), and ongoing pregnancy was achieved in 4 patients (7.8%). There was no statistically significant difference in terms of intrauterine insemination success between the control group with TSH <2.5 mIU / L and the study group with TSH 2.5-4.5 mIU/L. Widespread randomized controlled prospective studies need to determine the optimal TSH threshold value before TSH treatment of the women receiving infertility treatment
Risk of developing subclinical hypothyroidism among individuals with TSH values 2.5-4.2 miU/L [Tsh değerlerі 2,5-4,2 miu/l araliğinda bulunan bіreylerіn subklіnіk hіpotіroіdі gelіştіrme rіskіtsh]
No full textObjective: Estimating the serum thyroid stimulating hormone (TSH) concentration is the most sensitive test to show thyroid function. TSH values of 95 percent of the population fall between 0.3-2.5 mIU/L. Although lower limits of the reference interval is certain, upper limits remains controversial. Research data indicate that individuals with TSH values outside the 2.5-3.0 mIU/L interval are under risk for thyroid disorders. The purpose of this study is to investigate the time dependent subclinical hypothyroidism risk of the individuals with TSH values over 2.5 mIU/L. Material and Method: The research is composed of three groups including healthy subjects with TSH values between 0.27-2.5 mIU/L (n=55) with negative thyroid peroxidase antibody (TPO Ab) and thyroglobulin antibody (TG Ab) values and cases with TSH values between 2.5-4.2 mIU/L and with positive (60) and negative (n=212) anti-TPO and anti-TG levels. The data are surveyed retrospectively and the difference between the past and present TSH levels are investigated. For statistical analysis paired and unpaired t-test is used. Results: In all groups statistically meaningful elevation of time dependent TSH values were found. While in the group with TSH values between 2.5-4.2 mIU/L and negative thyroid antibodies the risk of subclinical hypothyroidism was calculated as 23% for the first 5 years, for the group with positive antibodies it was found to be 30%. TSH values 0.27-2.5 mIU/L no subclinical hypothyroidism was evident in 5 years of duration. Conclusion: The results showed that individuals with TSH values between 2.5-4.2 mIU/L are under risk for subclinical hypothyroid independent of thyroid antibody concentration. © 2016, Nobelmedicus. All rights reserved
A first-trimester serum TSH in the 4-10 mIU/L range is associated with obstetric complications in thyroid peroxidase antibody-negative women
No full textPurpose The impact of mild subclinical hypothyroidism on pregnancy outcomes in TPOAb-negative women is poorly explored. The aim of the present study was the evaluation in a wide cohort of TPOAb-negative pregnant women the role of subclinical hypothyroidism (SCH) on several pregnancy outcomes. Methods The study included women aged & GE; 18 years with a singleton pregnancy without known thyroid disease with serum TSH concentration between 0.4 and 10 mIU/L and TPOAb negative. Data about clinical and demographic features were collected. A blood sample was drown to test TSH, TPOAb, ANA and ENA concentration. The mean uterine artery pulsatility index was measured. Risk of adverse obstetric and fetal outcomes was collected. Results The cohort included 2135 pregnant women. Pregnant women with TSH 4-10 mUI/L had a significantly higher frequency of family history of thyroid diseases, and personal history of celiac disease diseases, type 1 diabetes mellitus, rheumatic disease, antinuclear antibody (ANA) and anti-extractable nuclear antigen (ENA) positive tests. The risk for pre-eclampsia and small for gestational age (SGA) was significantly higher in pregnant women with first-trimester TSH 4-10 mIU/L. A first-trimester TSH serum level greater than 4 mIU/L was associated with a significant increase in the occurrence of abnormal uterine artery pulsatility index, with a more than threefold increase in the risk of developing pre-eclampsia and with the risk of SGA. Conclusions In TPOAb-negative pregnant women, a first-trimester serum TSH level ranging from 4 to 10 mIU/L is significantly and independently linked to an increased uterine artery pulsatility index as well as to negative pregnancy outcomes such as pre-eclampsia, SGA and gestational diabetes
RISK OF DEVELOPING SUBCLINICAL HYPOTHYROIDISM AMONG INDIVIDUALS WITH TSH VALUES 2.5-4.2 mIU/L
No full textObjective: Estimating the serum thyroid stimulating hormone (TSH) concentration is the most sensitive test to show thyroid function. TSH values of 95 percent of the population fall between 0.3-2.5 mIU/L. Although lower limits of the reference interval is certain, upper limits remains controversial. Research data indicate that individuals with TSH values outside the 2.5-3.0 mIU/L interval are under risk for thyroid disorders. The purpose of this study is to investigate the time dependent subclinical hypothyroidism risk of the individuals with TSH values over 2.5 mIU/L. Material and Method: The research is composed of three groups including healthy subjects with TSH values between 0.27-2.5 mIU/L (n=55) with negative thyroid peroxidase antibody (TPO Ab) and thyroglobulin antibody (TG Ab) values and cases with TSH values between 2.5-4.2 mIU/L and with positive (60) and negative (n=212) anti-TPO and anti-TG levels. The data are surveyed retrospectively and the difference between the past and present TSH levels are investigated. For statistical analysis paired and unpaired t-test is used. Results: In all groups statistically meaningful elevation of time dependent TSH values were found. While in the group with TSH values between 2.5-4.2 mIU/L and negative thyroid antibodies the risk of subclinical hypothyroidism was calculated as 23% for the first 5 years, for the group with positive antibodies it was found to be 30%. TSH values 0.27-2.5 mIU/L no subclinical hypothyroidism was evident in 5 years of duration. Conclusion: The results showed that individuals with TSH values between 2.5-4.2 mIU/L are under risk for subclinical hypothyroid independent of thyroid antibody concentration
Newborn Screening TSH Values Less Than 15 mIU/L Are Not Associated With Long-term Hypothyroidism or Cognitive Impairment
No full textBackground: It is unclear whether newborns with mild thyrotropin elevation (mTSHe) are at risk of neurocognitive impairment. We assessed whether mTSHe at birth persists during childhood and compared neurocognitive functioning to siblings.Methods: This study encompassed children born in the Auckland region (New Zealand) with a newborn screen TSH level of 8 to 14 mIU/L blood, age 6.9 to 12.6 years at assessment, and their siblings. Thyroid function tests (serum TSH and free thyroxine) and neurocognitive assessments were performed, including IQ via the Wechsler Intelligence Scale for Children, fourth edition.Results: Ninety-six mTSHe individuals were studied, including 67 children recruited with 75 sibling controls. Mean mTSHe newborn TSH level was 10.1 mIU/L blood and 2.4 mIU/L at assessment (range, 0.8-7.0 mIU/L, serum). Although higher newborn TSH levels in the mTSHe group correlated with lower full-scale IQ scores (r = 0.25; P =.040), they were not associated with the magnitude of the IQ difference within sibling pairs (P =.56). Cognitive scores were similar for mTSHe and controls (full-scale IQ 107 vs 109; P =.36), with a minor isolated difference in motor coordination scores.Conclusions: Our data do not suggest long-term negative effects of neonatal mild TSH elevation. TSH elevation below the screen threshold appears largely transient, and midchildhood neurocognitive performance of these children was similar to their siblings. We propose that associations between neonatal mild TSH elevation and IQ are due to familial confounders. We caution against the practice of reducing screening CH cutoffs to levels at which the diagnosis may not offer long- term benefit for those detected.</p
Association of TSH Levels in the Therapeutically Neglected Range of 6.5–8 mIU/L with Significant Changes in Liver and Kidney Function: A Retrospective Study of the Kashmiri Population
No full textBackground: The thyroid gland secretes hormones crucial for growth, differentiation, regulation of metabolic processes, and homeostasis. In response to underactivity of this gland, the pituitary secretes thyrotropin, also known as the thyroid-stimulating hormone (TSH). Medication for thyroid hypofunction is usually started when TSH levels exceed 10 mIU/L. However, we hypothesize that TSH levels much below this therapeutic threshold level may herald significant renal and hepatic dysfunction. The present study was thus conducted to assess liver and kidney function parameters in cases having TSH in the subclinical range with particular focus on the therapeutically neglected (6.5–8 mIU/L) range.
Methods: Hospital laboratory archives of 297 adults with laboratory evidence of hypothyroidism, that is, TSH > 6.5 mIU/L, were retrieved and compared with data obtained from 430 euthyroid hospital controls, that is, TSH < 2.5 mIU/L, also from the same period. The thyroid profile and clinical chemistry analyses were performed on Beckman Coulter’s UniCel DxI 800 and AU 5800, respectively. SPSS version 20 was used to analyze the results.
Results: Significant differences in triiodothyronine (T3), thyroxine (T4), TSH, urea, creatinine, total bilirubin, total protein (TP), and liver enzymes were observed between cases with TSH > 6.5 mIU/L and controls (P < 0.05). There was also a significant difference in T4, TSH, urea, creatinine, total bilirubin, albumin and aspartate aminotransferase (AST) among cases with TSH in the range of 6.5–8 mIU/L when compared with controls (P < 0.05). A correlation of T3 with TSH, urea, and creatinine was seen (P < 0.05). No correlations between TSH and other clinical chemistry parameters could be observed. However, in the 6.5–8 mIU/L subgroup, correlation of TSH was seen with TP and albumin only.
Conclusion: Authors found that, as a rule, subtle renal and hepatic dysfunction were established in cases with TSH levels <8 mIU/L, which was below the typical “therapeutic cut-off” of 10 mIU/L. Accordingly, we advocate against incautiousness and suggest regular monitoring, especially in the 6.5–8 mIU/L range
Clearing the Skepticism about Subclinical Hypothyroidism: Is It Beneficial to Treat Patients with Thyroid-Stimulating Hormone >4.5 and <10 mIU/L?
No full textSubclinical hypothyroidism (SCH) is a heterogeneous clinical condition ranging from asymptomatic to wide variety of clinical manifestations, which are often nonspecific. Being a common laboratory finding, clinicians often face the dilemma of whether to treat or not. Threshold of 10 mIU/L of thyroid-stimulating hormone (TSH) is often used as a cutoff limit to offer treatment. However, still, debate remains on whether to treat less than 10 mIU/L considering special clinical conditions like pregnancy. Whether SCH exists, is screening needed in asymptomatic individuals, is treating asymptomatic cases beneficial or harmful and what threshold level of TSH to be considered for treatment are all potential questions that need to be answered
Field and temperature dependence of the current-voltage characteristics of Bi2Sr2Ca2Cu3O10/Ag multifilimentary tapes
No full textThe current-voltage characteristics of Bi[2]Sr[2]Ca[2]Cu[3]O[10]/Ag multifilamentary tapes were measured at different temperatures close to the critical temperature and in different applied magnetic fields up to 1000 Oe. The data were interpreted in terms of thermally activated flux creep by using an intermediate phenomenological model that takes into account the collective pinning. Temperature and field dependences of the pinning potential and of the collective pinning exponent were determined through numerical analysis
Incidence of elevation of serum thyroid-stimulating hormone during controlled ovarian hyperstimulation for in vitro fertilization
No full textObjective To evaluate the rate of euthyroid women encountering an elevation of serum TSH above the threshold of 2.5 mIU/L during controlled ovarian hyperstimulation (COH) for IVF. Study design Six-month prospective cohort study on 175 consecutive euthyroid women undergoing their first IVF cycle. Serum TSH assessments were performed before COH, at the time of hCG administration and at +16 days after hCG administration. Women were eligible if serum TSH tested the month preceding the IVF cycle was 0.4-2.5 mIU/L. A history of thyroid disorders was an exclusion criterion. Results Serum concentrations of TSH at the three scheduled assessments were 1.5 ± 0.5, 2.2 ± 1.0 and 2.1 ± 1.1 mIU/L, respectively. A statistically significant increase occurred between basal levels and levels at the time of hCG administration (p < 0.001). Afterwards, levels remained stable (p = 0.49). Serum TSH at the time of hCG administration exceeded the threshold of 2.5 mIU/L in 61 subjects, corresponding to 35% (95%CI: 28-42%). At +16 days after hCG administration, this event was observed in 47 subjects (27%, 95%CI: 21-34%). Baseline characteristics of women who did and did not exceed the threshold were similar apart from basal serum TSH, which was higher in the former group. The OR was 7.6 (95%CI: 2.9-20.2) per mIU/L (p < 0.001). Cycle outcome and pregnancy rate were also similar. Conclusion Serum TSH exceeds the threshold of 2.5 mIU/L during COH in one out of three women who are euthyroid prior to enter an IVF cycle. Further evidence is warranted to elucidate the clinical relevance of our findings
Current-voltage characteristics of Bi<sub>2</sub>Sr<sub>2</sub>Ca<sub>2</sub>Cu<sub>3</sub>O<sub>10</sub>+x/Ag multifiliamentary tapes in zero applied magnetic field
No full textCurrent - voltage characteristics of multifilamentary Bi2Sr2Ca2Cu3O10/Ag tapes (short samples) produced by the 'powder in tube' technique were measured at different temperatures close to the mean-field critical temperature, and in zero applied magnetic field. After performing the required corrections due to the current flowing in the silver matrix, the I - V curves were interpreted in terms of current-induced unbinding of the thermally created vortex - antivortex pairs. Two possible mechanisms for appearance of a finite critical current in zero applied magnetic field are discussed: the Jensen - Minnhagen quasi-two-dimensional (2D) approach, that takes into account the interlayer Josephson coupling, and a model of size limitation of vortex fluctuations. From our analysis, it seems that the latter model is more suitable for this kind of superconducting material, due probably to an accentuated intrinsic anisotropy
- …
